HUMANIZED RECOMBINANT VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN (hrVCP) FOR PROTECTION OF COGNITIVE FUNCTION
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other forms of dementia, particularly in individuals with the APOE ε4 allele, offer limited benefits and can cause adverse effects, and there is a need for safe and effective delivery methods to the central nervous system to inhibit neuroinflammation and protect cognitive function.
Innovation Solution
Intranasal administration of a humanized recombinant complement inhibitory protein (hrVCP) to inhibit the complement system, which is administered via inhalation devices, nasal sprays, or nasal tubes, targeting neuroinflammation independent of amyloid and tau pathology to protect cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current amyloid-targeting therapies are used for AD treatment, then cognitive function may be improved, but serious adverse events occur particularly in APOE ε4 carriers
Solution Approach 1:
The patent converts the harmful effect of complement activation (which causes neuroinflammation and neuronal damage) into a beneficial target for therapy. By developing hrVCP that specifically inhibits complement activation, the patent turns the previously harmful immune response into a controllable mechanism, protecting neurons from complement-mediated damage while maintaining safety in APOE ε4 carriers.
Solution Approach 2:
The patent changes the therapeutic target from amyloid plaques to complement activation parameters. By measuring and modulating complement activation levels rather than amyloid burden, the patent creates a safer treatment parameter that avoids the harmful effects of amyloid-targeting therapies while still addressing the root cause of neuroinflammation in AD.
2Reliability
If IV administration by skilled physician is used for CNS drug delivery, then treatment effectiveness is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent uses the nasal mucosa as an intermediary delivery route between the external environment and the CNS. Instead of requiring direct IV injection by skilled physicians, the nasal spray formulation uses the nasal cavity as a bridge to deliver hrVCP into the CNS, simplifying administration while maintaining effectiveness through the blood-brain barrier.
Solution Approach 2:
The patent replaces the complex mechanical IV administration system with a simpler nasal spray delivery mechanism. The nasal route eliminates the need for sterile IV techniques, skilled injection skills, and medical supervision, substituting a simple self-administerable spray system for complex medical procedures.
3Productivity
If complement system is activated to clear amyloid plaques, then AD pathology is addressed, but neuroinflammation and neuronal damage increase
Solution Approach 1:
The patent extracts the harmful component (complement activation) from the therapeutic process. Instead of relying on complement activation to clear amyloid plaques, the patent separates amyloid clearance mechanisms from complement system engagement, using hrVCP to specifically inhibit complement activation and prevent neuroinflammation while addressing AD pathology through alternative means.
Solution Approach 2:
The patent converts the harmful neuroinflammation caused by complement activation into a target for therapy. By developing hrVCP that specifically blocks complement activation, the patent turns the previously harmful immune response into a protected state, preventing neuronal damage while maintaining amyloid clearance through non-complement mechanisms.
Data Source
AI summary
A method of reducing an APOE ε4 mediated cognitive deficit is provided and comprises administering to a subject in need thereof an effective amount of a recombinant vaccinia virus complement control protein (hrVCP) polypeptide having a modified amino acid sequence including one or more amino acid substitutions to an amino acid sequence as set forth in SEQ ID NO: 2, wherein the one or more amino acid substitutions are selected from the group consisting of H98Y, E102K, E108K, E120K, and combinations thereof, provided at least one of the substitutions is E102K. Methods of treating dementia characterized by an APOE ε4 mediated cognitive deficit and methods of reducing complement activation mediated by APOE ε4 are further provided an include administration of the hrVCP polypeptide.